continu
threat
pose
newli
emerg
reemerg
infecti
diseas
mani
viral
origin
review
past
decad
global
effort
meet
challeng
result
enhanc
abil
identifi
genet
fingerprint
caus
agent
often
extraordinari
speed
seen
sever
acut
respiratori
syndrom
sar
episod
swine
influenza
pandem
howev
speed
acquir
genet
inform
caus
agent
newli
emerg
infecti
diseas
match
speed
develop
suitabl
treatment
genet
inform
episod
sar
could
translat
equal
rapid
develop
new
therapi
sinc
drug
discoveri
highthroughput
screen
ht
ration
design
requir
inform
easili
deriv
knowledg
viral
genom
addit
novel
emerg
virus
resourc
requir
classic
drug
discoveri
easili
mobil
diseas
limit
market
potenti
andor
sporad
outbreak
howev
exactli
situat
immedi
avail
specif
easi
use
ht
amen
system
would
valuabl
sinc
would
allow
rapid
test
potenti
antivir
immun
activ
envelop
virus
possibl
identifi
envelop
glycoprotein
directli
genet
inform
rapidli
produc
synthet
cdna
correspond
key
domain
viral
fusion
machineri
report
outlin
strategi
rapidli
predict
transform
cdna
amen
screen
tool
therebi
identifi
common
screen
platform
applic
multipl
pathogen
salient
inform
envelop
glycoprotein
cdna
identifi
bioinformat
analysi
viral
genom
screen
antivir
molecul
high
potenc
accept
pharmacolog
properti
use
simpl
protocol
develop
neutral
antibodi
andor
dna
vaccin
valid
screen
strategi
show
use
screen
neutral
antibodi
infect
popul
nipah
niv
hendra
hev
virus
two
close
relat
recent
emerg
caus
agent
zoonosi
capabl
caus
signific
mortal
human
anim
sinc
emerg
niv
hev
virus
reemerg
sever
time
recent
outbreak
show
case
nipah
well
document
persontoperson
transmiss
almost
everi
year
sinc
viru
flare
bangladesh
kill
peopl
last
decad
vaccin
avail
either
viru
although
protein
dna
vaccin
approach
appear
potenti
effect
altern
passiv
immunotherapi
shown
effect
cat
hamster
recent
ferret
model
diseas
howev
niv
hev
agent
limit
rapid
develop
antibodi
make
larg
scale
screen
antivir
compound
difficult
gener
monoclon
antibodi
use
cdna
immun
highli
valuabl
rapid
develop
immun
strategi
broad
rang
virus
particularli
case
new
emerg
virus
show
cdna
obtain
viral
genom
inform
suffici
immun
anim
immun
elicit
antibodi
effect
live
virus
cdna
also
prepar
directli
sequenc
bioinformat
inform
viral
glycoprotein
offer
quick
rout
passiv
immun
key
util
screen
approach
describ
use
gene
encod
envelop
glycoprotein
deriv
target
viru
quickli
assess
potenti
antivir
transfect
cell
plasmid
encod
target
viru
envelop
glycoprotein
infect
cell
vesicular
stomat
viru
vsv
lack
gene
entri
glycoprotein
g
pseudotyp
vsv
g
system
observ
multicycl
replic
mcr
target
viru
iedn
transfect
cell
subsequ
assess
antivir
agent
abil
inhibit
viral
spread
method
sever
advantag
perform
safe
condit
need
produc
pseudotyp
virus
new
emerg
viru
quantit
result
obtain
within
hour
success
establish
platform
demonstr
multicycl
replic
condit
influenza
viru
pathogen
addit
pathogen
junin
viru
niv
recent
describ
lujo
viru
proof
concept
principl
appli
easili
virus
previous
describ
similar
assay
mimick
multicycl
replic
hev
new
assay
report
howev
requir
specif
pseudotyp
produc
primari
infect
henc
reduc
time
requir
set
assay
method
tailor
new
emerg
viru
pseudotyp
virion
bear
vsvg
requir
primari
infect
prepar
advanc
high
titer
allow
rapid
screen
possibl
antivir
agent
includ
antibodi
carri
cell
reflect
natur
host
tissu
addit
screen
assay
adapt
immunolog
diagnost
analysi
envisag
pseudotyp
mcr
assay
platform
technolog
enabl
prepar
storag
specif
set
assay
reagent
wide
rang
viral
pathogen
low
cost
advanc
actual
outbreak
correspond
viral
diseas
could
form
basi
efficaci
time
outbreak
respons
immedi
follow
identif
danger
new
virus
multicycl
replic
assay
describ
previous
well
amen
assay
requir
product
pseudotyp
stock
specif
new
emerg
viru
significantli
add
time
requir
establish
assay
new
viru
order
facilit
univers
applic
technolog
establish
simpl
system
multipl
virus
use
evalu
antivir
antibodi
efficaci
modifi
origin
assay
use
singl
pseudotyp
viru
infect
pseudotyp
viru
use
system
prepar
vsv
background
use
vsv
delta
g
pseudotyp
vsv
g
enabl
viru
entri
mediat
vsv
g
result
subsequ
round
infect
vsv
suppli
envelop
glycoprotein
new
viru
tran
result
viru
product
releas
pseudotyp
new
viru
mimic
nativ
viru
term
infect
replic
releas
see
fig
test
concept
cell
transfect
plasmid
encod
surfac
glycoprotein
niv
gf
concomitantli
yfp
yellow
fluoresc
protein
allow
visual
transfect
transfect
cell
either
infect
pseudotyp
carri
rfp
allow
visual
infect
cell
left
uninfect
set
control
well
cell
transfect
control
plasmid
also
infect
pseudotyp
viru
viru
underw
multicycl
replic
transfect
cell
indic
increas
rfp
express
time
infect
fig
even
though
initi
infect
event
mediat
vsv
pseudotyp
viru
second
subsequ
round
niv
due
express
transfect
glycoprotein
gf
highthroughput
screen
ht
univers
measur
assay
qualiti
robust
z
valu
valu
consid
perfect
assay
valu
requir
valu
multicycl
replic
compar
uninfect
control
tabl
render
amen
ht
parallel
test
whether
cdna
immun
would
gener
antibodi
high
neutral
activ
specif
rabbit
immun
pcaggshev
f
pcaggshev
g
serum
collect
immun
anim
test
origin
mcr
assay
format
briefli
cell
transfect
niv
fg
concomitantli
venusyfp
infect
pseudotyp
niv
infect
measur
hr
post
infect
read
intens
rfp
express
polyclon
antibodi
rabbit
inhibit
infect
origin
pseudotyp
viral
entri
assay
format
use
niv
pseudotyp
vsv
fig
small
amount
cellcel
fusion
seen
presenc
antihev
g
antibodi
antihev
f
antibodi
complet
inhibit
fusion
howev
antihev
g
antibodi
especi
rabbit
gave
better
dose
respons
antihev
f
antibodi
fig
test
univers
approach
immun
rat
cdna
gener
antibodi
niv
g
five
rat
immun
pcaggsniv
g
first
step
serum
five
rat
collect
test
inhibit
infect
modifi
mcr
assay
infect
measur
hr
infect
polyclon
antibodi
three
rat
rel
low
titer
neutral
activ
polyclon
antibodi
rat
rat
much
stronger
neutral
properti
fig
show
greater
inhibit
higher
dilut
rat
monoclon
antibodi
also
gener
immun
rat
pcaggsniv
g
test
mcr
assay
concentr
mgml
monoclon
antibodi
show
inhibit
infect
fig
howev
lower
concentr
mgml
antibodi
inhibit
infect
antibodi
abl
inhibit
infect
monoclon
antibodi
specif
niv
g
fac
analysi
data
shown
consid
possibl
cdna
immun
strategi
may
elicit
antibodi
neutral
live
virus
conform
protein
produc
cdna
could
significantli
differ
viral
particl
result
induct
antibodi
whose
specif
could
significantli
differ
induc
viral
infect
exampl
immun
high
concentr
ebola
gp
induc
neutral
antibodi
contrast
immun
vlp
vsvebola
gp
chimer
viru
induc
neutral
antibodi
valid
strategi
live
nipah
hendra
virus
perform
vitro
neutral
assay
tabl
neutral
capac
polyclon
rabbit
monoclon
rat
antibodi
gener
compar
murin
mab
antiniv
f
previous
report
neutral
niv
hev
although
rabbit
polyclon
antihev
g
sera
exhibit
neutral
capac
dilut
test
rabbit
polyclon
antihev
f
antibodi
neutral
hev
one
neutral
niv
infect
well
rat
monoclon
antiniv
g
antibodi
inhibit
niv
infect
one
neutral
hev
well
togeth
result
demonstr
immun
strategi
appli
studi
allow
gener
antivir
polyclon
monoclon
antibodi
neutral
live
virus
valid
modifi
pseudotyp
viru
assay
compar
result
two
rat
polyclon
antibodi
rais
niv
g
use
assay
describ
modifi
mcr
assay
antibodi
inhibit
multicycl
replic
niv
pseudotyp
viru
unmodifi
version
multicycl
replic
assay
use
niv
pseudotyp
infect
fig
newli
modifi
assay
describ
use
pseudotyp
vsv
entri
fig
howev
effect
modifi
assay
fig
lower
compar
inhibit
obtain
pseudotyp
niv
use
infect
viral
fusion
inhibitor
found
efficaci
inhibit
viral
entri
necessarili
correl
vivo
protect
abil
inhibitor
block
spread
viru
monolay
cell
infect
correl
posit
vivo
efficaci
thu
platform
allow
quick
screen
antivir
may
also
help
accur
estim
effect
compound
importantli
perhap
explain
appar
lower
antivir
efficaci
newli
modifi
assay
assay
account
context
viral
spread
distinct
mere
entri
event
abil
curtail
multicycl
replic
even
infect
occur
like
provid
import
advantag
success
antivir
therapi
assay
establish
investig
applic
system
virus
purpos
cell
transfect
plasmid
encod
surfac
glycoprotein
lujo
viru
fig
junin
viru
fig
vsv
fig
concomitantli
yfp
yellow
fluoresc
protein
allow
visual
transfect
transfect
cell
either
infect
pseudotyp
carri
rfp
allow
visual
infect
cell
left
uninfect
addit
control
cell
transfect
control
plasmid
also
infect
pseudotyp
viru
singl
cycl
virus
underw
multicycl
replic
cell
transfect
cdna
viral
glycoprotein
indic
increas
rfp
express
time
post
infect
fig
observ
minim
differ
rfp
express
cell
initi
round
infect
expect
length
incub
increas
subsequ
round
infect
occur
multicycl
system
rfp
express
becam
fold
higher
transfect
cell
hour
respect
reveal
rapidli
adapt
system
permit
assess
viral
infect
antivir
efficaci
envelop
viru
valu
multicycl
replic
compar
uninfect
control
tabl
assay
perform
well
plate
format
show
small
deviat
larg
number
replic
confirm
modifi
assay
use
specif
antivir
efficaci
evalu
test
chloroquin
data
shown
previous
shown
inhibit
henipaviru
multicycl
replic
virus
mcr
assay
chloroquin
show
high
antivir
activ
niv
littl
activ
virus
concentr
lower
chloroquin
use
effect
block
vsv
mcr
assay
expect
note
chloroquin
posit
control
cell
base
assay
intend
comparison
vivo
efficaci
addit
util
novel
emerg
virus
modifi
assay
format
appli
highli
pathogen
influenza
virus
requir
facil
adapt
mcr
assay
evalu
replic
influenza
viru
observ
multicycl
replic
viru
use
tpck
treat
trypsin
treatment
neuraminidas
treatment
modifi
assay
fig
valu
multicycl
replic
compar
uninfect
control
passiv
immunotherapi
address
problem
quickli
treat
protect
larg
popul
peopl
possibl
exposur
viru
especi
absenc
vaccin
passiv
immun
ideal
case
probabl
exposur
infect
low
caus
agent
unidentifi
howev
quick
gener
antibodi
key
effect
immun
plan
particularli
case
emerg
virus
one
problem
hinder
develop
passiv
immunotherapi
effect
gener
antibodi
tradit
antibodi
rais
either
deadattenu
form
caus
agent
entir
subunit
protein
involv
infect
howev
method
suffer
problem
puriti
amount
though
high
level
immun
usual
gener
cdna
immun
avoid
problem
sinc
viral
glycoprotein
express
cell
surfac
anim
allow
antibodi
rais
nativ
form
protein
thu
attain
high
activ
specif
method
particularli
suit
gener
antibodi
membran
protein
show
cdna
immun
rat
use
cdna
correspond
surfac
glycoprotein
virus
niv
exampl
effect
gener
monoclon
antibodi
whose
activ
specif
test
use
platform
adapt
broad
rang
virus
import
advantag
cdna
immun
method
rest
sequenc
inform
viral
genom
case
envelop
glycoprotein
unidentifi
infect
includ
zoonos
recent
adapt
infect
human
often
transport
infecti
agent
possibl
limit
develop
antibodi
sinc
resourc
requir
antibodi
gener
may
close
site
viral
detect
especi
true
emerg
diseas
highlight
repeat
niv
reemerg
rural
bangladesh
case
cdna
immun
offer
fast
effect
way
gener
antibodi
specif
neutral
activ
viru
investig
result
indic
antibodi
rais
cdna
immun
neutral
live
viru
interestingli
sever
antif
antibodi
rais
hendra
f
also
block
nipah
infect
monoclon
antiniv
g
mab
neutral
niv
one
exhibit
signific
crossneutr
hendra
viru
data
taken
togeth
previous
publish
report
may
indic
elicit
antif
antibodi
least
cdna
immun
may
lead
broadli
neutral
antibodi
use
passiv
immunotherapi
advantag
gener
immun
immedi
patient
howev
evalu
neutral
activ
potenti
therapeut
antibodi
requir
infect
cell
viru
interest
limit
problem
antibodi
gener
viru
pathogen
like
niv
hev
difficulti
associ
transport
viru
point
detect
suitabl
laboratori
assay
describ
overcom
problem
use
pseudotyp
virus
infect
cell
express
glycoprotein
viru
thu
neutral
activ
antibodi
analyz
evalu
use
assay
simul
multicycl
replic
viru
condit
increas
speed
develop
effect
antibodi
protect
also
significantli
reduc
test
cost
mcr
assay
distinguish
antibodi
differ
neutral
activ
specif
replic
antivir
select
seen
live
virus
antibodi
show
high
inhibit
low
dilut
may
due
nonspecif
interact
surfac
glycoprotein
weak
antibodi
show
low
level
infect
inhibit
one
hurdl
address
current
studi
relat
possibl
monoclon
antibodi
develop
use
cdna
immun
rat
associ
risk
invok
immun
respons
human
antirat
antibodi
event
negat
intend
therapeut
effect
antibodi
fortun
task
human
arriv
product
recogn
antigen
recipi
rel
straight
forward
next
phase
research
plan
use
cdna
immun
mice
genet
modifi
produc
human
antibodi
human
monoclon
antibodi
nipah
g
shown
partial
protect
ferret
anim
model
antibodi
identifi
screen
human
fab
librari
solubl
g
protein
strategi
describ
manuscript
would
allow
direct
identif
neutral
human
monoclon
antibodi
without
intermedi
step
propos
system
describ
could
design
kit
includ
genet
materi
ultim
requir
specif
viral
cdna
mix
togeth
transfect
mixtur
addit
cell
cost
effect
transfect
reagent
would
major
advantag
kit
therefor
adapt
assay
use
pei
transfect
bring
cost
transfect
reagent
sever
fold
render
system
feasibl
low
budget
system
propos
limit
screen
antivir
target
entri
step
viral
life
cycl
requir
viral
envelop
protein
compat
vsv
summari
propos
novel
platform
screen
antivir
compound
antibodi
newli
emerg
virus
assay
establish
rapidli
use
sequenc
inform
new
emerg
virus
assay
highli
reproduc
sensit
perform
facil
provid
safe
method
potenti
highli
pathogen
newli
emerg
virus
otherwis
requir
contain
facil
assay
behav
consist
low
cell
number
thu
allow
miniatur
well
format
make
amen
highthroughput
screen
concept
also
easili
appli
primari
cell
may
reveal
differ
antivir
potenc
laboratori
adapt
monolay
use
comparison
unmodifi
multicycl
replic
assay
strategi
also
reveal
differ
agent
inhibit
entri
agent
inhibit
tissu
spread
virus
human
kidney
epitheli
vero
african
green
monkey
kidney
cell
grown
dulbecco
modifi
eagl
medium
dmem
mediatechcellgro
supplement
fetal
bovin
serum
antibiot
pseudotyp
virus
gener
use
recombin
vsv
deriv
cdna
vsv
indiana
g
gene
replac
dsred
gene
rfp
pseudotyp
niv
f
g
gener
describ
previous
briefli
cell
transfect
plasmid
encod
vsvg
nivfg
five
hour
posttransfect
dish
wash
infect
multipl
infect
moi
complement
vsvg
supernat
fluid
contain
pseudotyp
viru
niv
fg
vsvg
collect
h
postinfect
store
niv
isol
cerebrospin
fluid
patient
receiv
dr
kb
chua
dr
sk
lam
univers
malaya
kuala
lumpur
malaysia
hev
obtain
graham
lloyd
exot
viru
bank
porton
england
niv
hev
stock
prepar
infect
cell
previous
describ
inserm
jean
biosafeti
level
laboratori
lyon
franc
chloroquin
diphosph
salt
obtain
mp
biomed
cat
describ
previous
nivfg
glycoprotein
pseudotyp
onto
result
pseudotyp
virus
use
infect
niv
fgexpress
cell
moi
simul
multicycl
replic
rfp
product
hr
analyz
micropl
fluoresc
reader
spectramax
detect
rfp
express
level
well
read
excit
emiss
detect
yfp
express
well
read
excit
emiss
modifi
multicycl
replic
assay
vsv
g
glycoprotein
pseudotyp
onto
result
pseudotyp
virus
use
infect
viral
glycoprotein
express
cell
simul
multicycl
replic
singlecycl
infect
assay
vsvg
pseudotyp
use
moi
infect
cell
transfect
control
plasmid
influenza
viru
ugml
tpck
trypsin
mu
neuraminidas
ad
well
polyclon
antibodi
rais
rabbit
antihev
f
antihev
g
rat
antinivg
cdna
immun
plasmid
express
either
hev
g
hev
f
niv
g
use
standard
commercailli
avail
protocol
genovac
monoclon
antibodi
produc
use
proprietari
protocol
genovac
use
niv
g
cdna
isotyp
mab
use
studi
niv
hev
neutral
antibodi
test
use
twofold
dilut
sampl
describ
previous
dilut
antibodi
incub
viru
pfuswel
microtit
plate
min
dmem
gibco
supplement
fc
total
vero
cell
ad
well
indic
cell
plate
incub
day
rel
neutral
titer
defin
reciproc
dilut
antibodi
sampl
complet
inhibit
cytopath
effect
either
niv
hev
gene
encod
influenza
ha
nipah
g
f
commerci
synthes
clone
pcagg
vector
junin
lujo
gpc
pcagg
dr
thoma
bries
cell
transfect
plasmid
encod
niv
gf
yfp
four
hour
post
transfect
antibodi
ad
indic
dilut
cell
infect
vsvg
pseudotyp
viru
niv
fg
pseudotyp
viru
moi
valu
use
assess
qualiti
use
valu
inhibitor
blank
microtit
plate
stdev
stdev
blank
averag
blank
